

THE BIOCHEMICAL EFFECTS OF DRUGS IN PREGNANCY

VOLUME 1: DRUGS ACTIVE ON THE NERVOUS,
CARDIOVASCULAR AND HAEMOPOIETIC SYSTEMS

A. ONNIS

and
P. GRELLA

THE BIOCHEMICAL EFFECTS OF DRUGS IN PREGNANCY

VOLUME 1: DRUGS ACTIVE ON THE NERVOUS,
CARDIOVASCULAR AND HAEMOPOIETIC SYSTEMS

A. ONNIS

Professor of Clinical Obstetrics
and Director of the Obstetric and Gynaecological Clinic
and

P. GRELLA

Professor of Prenatal Paediatrics
both of the University of Padua, Italy

Translation Editor:

PETER J. LEWIS

formerly Department of Clinical Pharmacology, Royal Postgraduate Medical School
now Research Director, Merrell International, France



ELLIS HORWOOD LIMITED
Publishers · Chichester

Halsted Press: a division of
JOHN WILEY & SONS
New York · Chichester · Brisbane · Toronto

This English Edition first published in 1984 by

ELLIS HORWOOD LIMITED

Market Cross House, Cooper Street, Chichester, West Sussex, PO19 1EB, England

The publisher's colophon is reproduced from James Gillison's drawing of the ancient Market Cross, Chichester.

Distributors:

Australia, New Zealand, South-east Asia:

Jacaranda-Wiley Ltd., Jacaranda Press,

JOHN WILEY & SONS INC.,

G.P.O. Box 859, Brisbane, Queensland 40001, Australia

Canada:

JOHN WILEY & SONS CANADA LIMITED

22 Worcester Road, Rexdale, Ontario, Canada.

Europe, Africa:

JOHN WILEY & SONS LIMITED

Baffins Lane, Chichester, West Sussex, England.

North and South America and the rest of the world:

Halsted Press: a division of

JOHN WILEY & SONS

605 Third Avenue, New York, N.Y. 10016, U.S.A.

© 1984 English Edition – Ellis Horwood Limited

Translation and adaptation of the second Italian language edition Copyright 1982 by Piccin Editore s.a.s., Padova, Italia. Translated by C.A. Friedman.

British Library Cataloguing in Publication Data

Onnis, A.

The biochemical effects of drugs in pregnancy.

Vol. 1: Drugs active on the nervous, cardiovascular and haemopoietic systems. –

(Ellis Horwood series in biochemistry and pharmacology in medicine and neuroscience)

1. Obstetrical pharmacology

I. Title II. Grella, P. III. I farmaci in gravidanza. *English*

615'.7 RG528

Library of Congress Card No. 84-9141

ISBN 0-85312-591-0 (Ellis Horwood Limited)

ISBN 0-470-20059-6 (Halsted Press)

Printed in Great Britain by Unwin Brothers of Woking.

COPYRIGHT NOTICE –

All Rights Reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, without the permission of Ellis Horwood Limited, Market Cross House, Cooper Street, Chichester, West Sussex, England.

Preface

Society has always striven to protect the pregnant woman. In ancient Greece and pharaonic Egypt special attention was paid to the diet, hygiene, and drug treatment of the expectant mother. The dangers of certain drugs in pregnancy were mentioned by Mauriceau in the second half of the 17th century. At the end of the 18th century the concept of birth malformations being due to 'divine anger' began to be replaced by more biological explanations. In the middle of the 19th century Da Reste [1] and others began research on experimental teratogenesis, and it was shown that some foetal malformations could be caused by chemicals.

Ancel (1933) [2] showed that chemical or physical agents could have a reproducible teratogenic effect in mammals and birds if applied at particular stages of development. However, concern about teratogenicity in human pregnancy is quite recent. In 1959 such possibilities were discussed [3], but it was the thalidomide disaster of 1960 which brought the subject to everyone's attention. Since that time the use of drugs in pregnancy has become a highly emotional issue. A logical approach to the problems of drugs in pregnancy is to gather information on drug safety in a systematic way, assessing the risk to benefit ratio for all drugs likely to be used in pregnant women. This is a mammoth task, but the present work is an attempt to do this in a comprehensive way.

In recent years, work on the teratogenicity of drugs has noticeably increased, but so far as the practising doctor is concerned the literature is not helpful. Package inserts which state 'To be used with caution in pregnancy' do not contain enough specific information to be useful.

In publishing this book we hope to provide more precise, more useful and more complete data. We hope that clinicians will respond by contributing their own experiences or drawing our attention to literature we have overlooked. In this way future editions may, we hope, be improved.

A. ONNIS

Bibliography

- [1] Da Reste: citato da Caderas de Kerleau: Bull. Féd. Soc. Gyn. Obst. 20, n. 1bis. 1968.
- [2] Ancel: citato da Caderas de Kerleau: Bull. Féd. Soc. Gyn. Obst. 20, n. 1bis, 1968.
- [3] Bartolomei G., Boniver G., Ferrante L., Gaburro D., Onnis A.: Relazione al Congresso Lombardo-Veneto di Ostetricia e Pediatria - Milano 31 maggio/1 giugno 1959; Min. Ped. 12, 51, 1960.
- [4] Onnis A.: Relazione al Congresso Congiunto delle Società Austriaca e Triveneta di Ostetricia e Ginecologia. - Bressanone 8-9 maggio 1970; Min. Gin. 25, 509, 1973.

The publishers are indebted to Monique Maxwell for her help with the proof reading and indexing of this work.

PUBLISHERS' NOTE

Since the safety of drugs and their administration to both pregnant and non-pregnant patients is constantly under medical and scientific review, it is always wise to check the most recent literature when prescribing drugs discussed in this book. Drugs quoted in the text are not necessarily in line with normal therapeutic drug doses prescribed to patients, as in most cases drugs in this book were prescribed on a purely experimental basis.

Introduction

There is no doubt that over-prescribing of drugs is a major problem in modern medicine, and nowhere is unnecessary use of drugs more dangerous than in pregnancy. On the other hand, modern drugs have made a major contribution to human health, and even in pregnancy drugs still play an important part in treating maternal diseases and in relieving pain in labour.

In an ideal world no medical treatment would be required in pregnancy, but the reality is that many women develop conditions requiring treatment when they are pregnant. An absolute ban on drug usage in pregnancy would not be practical, and in any case would be as logical a response to the thalidomide disaster as abolishing air travel after a single aircraft crash.

Unfortunately, not all responses to disasters are logical, and in the case of drugs in pregnancy some of the responses are not medical. The issue has become one of public policy and legal responsibility, and it even has a political dimension.

In this complex situation the prescribing doctor finds himself in difficulty. He is perhaps not well read in the science of teratogenicity, but he knows that the patient is half informed about the risk of drugs in pregnancy and will blame any adverse event in the pregnancy on the drugs which he prescribes.

In such a situation the doctor should be able to talk knowledgeably to the patient of risks and benefits for the drug concerned. It has been our aim to supply the information he requires. The present book is certainly not infallible, and no doubt some recommendations will change in the future as a result of new information. It is, however, as complete as we are able to make it. If there are errors or omissions we would be grateful to hear of them.

EFFECTS OF DRUGS ON THE FOETUS

The effects of drugs given to pregnant women, the embryo, or foetus are difficult to predict. A summary of the main considerations as to the effects of drugs on the products of conception will now be given, leaving a more detailed consideration for later [1, 2, 3, 4].

Maternal pharmacokinetics and pharmacodynamics

Large physiological changes occur in pregnancy. Maternal weight increases not only because of growth of the products of conception and expansion of the uterus but because of an increase in circulating blood volume and body water. There is an increase in oxygen consumption, in basal metabolism, cardiac output, and red cell mass; and there are changes in the distribution of cardiac output, with particular increases in uterine and renal blood flow. The resistance and tone of blood vessels all over the body are changed. There is a profound change in renal physiology; an increase in glomerular filtration rate and alterations in tubular function. This is not all, for there is a change in the metabolism of protein, lipids, and carbohydrates, and changes in electrolyte balance. The alterations that occur in plasma proteins could and do have an important bearing on the distribution of drugs, many of which are highly protein bound.

The alterations in coagulation factors have an obvious significance for the requirement of anticoagulants. In women who develop complications of pregnancy, such as diabetes, hypertension, and renal impairment, the situation is still more complicated.

Transplacental passage of drugs

The placenta is still widely thought of as being a barrier between the mother and the foetus. For the majority of drugs this is an erroneous concept. It is also worth remembering that prior to the development of the placenta some drugs will be present in the tubular and uterine secretions and in contact with the blastocyst even as it migrates towards the point of implantation. The mechanisms which regulate the transfer of drugs from mother to foetus are the following:

1. *Simple diffusion.* Most exogenous chemical substances, particularly those of low molecular weight, gain access to the foetus by diffusion. Of importance here are the concentration gradient, the area of exchange across the placenta, the structural characteristics of the placental tissue to be crossed, and the physicochemical nature of the drug itself. These last include the size and spatial conformation of the molecule, its degree of ionization, lipid solubility, and extent of binding to macroprotein molecules. Drugs which are undissociated and highly lipid soluble diffuse most rapidly.
2. *Facilitated diffusion.* Some substances pass more rapidly across the placenta because facilitatory mechanisms exist at the cellular membrane level. An example of this would be facilitated diffusion of iron.
3. *Active transport.* Some drugs are actively transported across the placenta by a process which uses metabolic energy. An example of this is the diuretic triamterene.
4. *Transport of metabolites.* Some drug molecules are transported into the foetus only after metabolic transformation. An example would be ascorbic acid.

5. *Direct transport.* Occasionally the maternal and foetal circulations are in direct contact, as evidenced by passage of foetal erythrocytes into the mother and vice versa. This is an infrequent occurrence, and it probably does not play any important role in the transfer of drugs.

Metabolic transformation of drugs in the placenta

Within the placenta drugs can be metabolized, and such metabolic transformation may make the drug either more or less biologically active. There are four fundamental processes of biotransformation: oxidation, reduction, hydrolysis, and conjugation. Hydroxylation is a particularly important example of oxidative metabolism, hydrogenation of double bonds is an important example of reduction while the breaking of amide and ester bonds are hydrolytic reactions. The formation of glucuronides and sulphates are examples of conjugation reactions.

Trophoblastic cells of the placenta contain an abundance of endoplasmic reticulum, the cellular organelle where microsomal enzymes which perform these functions are situated. In the placenta all these reactions take place. Phosphatases liberate energy-rich phosphate bonds, sulphatases participate in the synthesis of oestriol, amino oxidase and catechol-O-methyltransferase inactivate biogenic amines, and peptidases modify polypeptides such as angiotensin, oxytocin, and ADH.

The effects of drugs on placental function are of significance. Some drugs can enhance enzymic activity in the placenta by induction, and others can inhibit enzymic activities such as those involved in steroid metabolism, particularly processes of aromatization. Other drugs reduce the utilization of glucose by the placenta and can thus modify a principal energy substrate utilized by the foetus.

Distribution and transformation of drugs within the foetus

The distribution of drugs in foetal tissue has been studied in experimental animals by autoradiography following administration of a radioactive drug. The large amounts of data thus obtained in different animal species suggest that the distribution of drugs in the foetus is similar to that in the adult organism. However, there are differences, particularly in early pregnancy. The blood-brain barrier develops late in foetal life, so the distribution of drugs in the foetus shows some important differences from that in the adult.

Some examples of selectivity of uptake in different foetal organs which have practical significance are those of chloroquine fixing in the retina, of streptomycin and other aminoglycosides fixing in the acoustic nerve, and of iodine and antithyroid drugs being taken up by the thyroid. Tetracycline is concentrated in bone tissue and in dentine. Drug metabolizing enzymes within the foetus increase gradually as the foetus matures. Several studies have been done on human foetal tissue from legal abortions. In human foetal liver, there is a high capacity for oxidation of drugs, while reductive transformations and

corresponding to the most rapid phase of development and the most intense differentiation. However, many organs develop simultaneously, and hence multiple malformations are possible.

- (c) After the first trimester most organs have already been formed, with the exception of the genital apparatus. This remains still sensitive to teratogenic agents. The central nervous system matures gradually in the latter half of pregnancy, and so psychotropic drugs and sex hormones are able to produce modifications of postnatal behaviour and of gonadotrophin secretion by an action late in pregnancy.

Nature of the drug

Some drugs are selectively taken up by the foetal organs and hence cause selective malformations. Examples are lesions of the acoustic nerve caused by streptomycin and lesions of the limbs caused by thalidomide.

Genetics of the foetus

The genetic background of the foetus is extremely important. It modifies the gravity, localization, and frequency of malformations.

Animal species differ in their response to teratogenic agents. Herein lies the problem of teratogenicity tests in animals and their non-applicability to man.

Dose and time of administration

Teratogenic effects are very dependent upon dose and on duration of administration. A single dose may be either more or less damaging than repeated doses because of such effects as enzyme induction.

Some drugs have an effect on the gametes, usually during gametogenesis. Drugs with mutagenic effects of this sort include cytotoxic drugs, cinchona alkaloids, and podophyllum. Ionizing radiation has a similar effect.

Bibliography

- [1] Periti P.: *Farmacologia Pediatrica Perinatale*. - Soc. Universo Ed. - Roma, 1973.
- [2] Boreus L.D.: *Fetal Pharmacology*. - Raven Ed. - New York, 1973.
- [3] Mirkin B.L.: *Perinatal Pharmacology and Therapeutics*. - Academic Ed. - New York, 1976.
- [4] Grella P.: *Attual. Ost. Gin.* 15, 293, 1975.

Using this book

This book has been designed so that it can be readily consulted by clinicians on the use of therapeutic drugs in pregnancy. It gives information on possible teratogenic effects of all drugs in current use. For each drug the pharmacological actions are briefly described, as well as the effects on human pregnancy and lactation. A summary of animal pharmacology during pregnancy is included.

We wish to emphasize:

- (1) that the information given in this book is not to be regarded as absolute;
- (2) that data from experimental animals cannot be directly applied to man.

The drugs are listed according to pharmacological type and therapeutic use, grouping together drugs with similar clinical indications. In addition to the general names of the drugs (which are indexed) we have included chemical formulae and molecular weights, so as to precisely characterize them. Some proprietary names are included.

Each chapter (for example, 'General anaesthetics') includes a list of the drugs discussed in that chapter, with a codification of the recommendations for the use or non-use of each drug. The codes used are:

- NC:** Drugs not contra-indicated either in pregnancy or labour, when used in the normal therapeutic doses.
- P:** Precaution — drugs to be used with care, and only when absolutely necessary.
- C:** Drugs that are contra-indicated. Their use should be limited to cases of exceptional difficulty, and when recourse to other less contra-indicated drugs is not possible. In some instances, the drugs are absolutely contra-indicated in only certain stages of pregnancy (trimesters 1,2,3), in labour, or during lactation.

The entry relating to a particular drug starts with a single-sentence summary of recommendations. Where there is contra-indication, or the need for precaution, there follows a table showing the appropriate codes (C or P) and the stages to which they apply. Blanks in the table, or indeed the absence of a table, imply that the drug is not contra-indicated. Further detail is given in the text.

For some drugs we have found no information on clinical experience or animal experiments. The entries for these drugs are collected together at the

ends of the relevant chapters or sections of chapters: they are collectively preceded by a row of asterisks * * * * *

Comparative table of embryonic development in diverse animal species.

Compilation of data existing in current literature.

Gestational age is expressed in days (weeks).

	Man	Rat	Mouse	Rabbit	Chicken
Duration of pregnancy	280 (40)	22 (3.1)	19 (2.7)	33 (4.7)	21 (3) (incubation)
Implantation of blastocyst	7 (1)	5-6 (0.7-0.9)	7 (1)	6 (0.9)	—
Initiation of cardiac action Pronephros	22 (3.1)	10 (1.4)	—	—	1.5 (0.2)
Mesonephros	25 (3.6)	12 (1.7)	9.5 (1.4)	—	1.75 (0.25)
Thyroid outline	27 (3.9)	10 (1.4)	8.5 (1.2)	—	1.8 (0.25)
Outline of upper limbs	27 (3.9)	10.5 (1.5)	9.3 (1.3)	10.5 (1.5)	2.2 (0.3)
Outline of metanephros Outline of lungs	28 (4)	12.2 (1.75)	9.6 (1.4)	—	3 (0.4)
Outline of lower limbs	30 (4.3)	—	10.3 (1.5)	11 (1.6)	2.5 (0.4)
Initiation of ossification	41 (5.9)	17.5 (2.5)	12.5 (1.8)	—	8 (1.1)
Outline of ducts of Müller	40 (5.7)	13.5 (1.9)	—		4 (0.6)
Outline of testicles	45 (6.4)	14.5 (2.1)	—	20 (2.9)	5.5 (0.8)
Closure of palate	57 (8.1)	16.5 (2.4)	15 (2.1)	19.5 (2.8)	—

Table of Contents

Preface	vii
---------------	-----

Introduction	ix
--------------------	----

Using this book	xiv
-----------------------	-----

Part 1 Drugs acting on the central and peripheral nervous systems and on synaptic junctions

1. General anaesthetics	2
2. Narcotic analgesics	22
3. Local anaesthetics	37
4. Hypnotics	45
5. Tranquillizers	65
6. Anticonvulsants	119
7. Antidepressants	130
8. Appetite depressants and central stimulants	155
9. Sympathomimetics	164
10. Parasympathomimetics	189
11. Parasympatholytics and spasmolytics	194
12. Muscle relaxants	229
13. Histamines and antihistamines	238
14. Serotonin, antiserotonins, ergot alkaloids, sympatholytics	260

Part 2 Drugs acting on the cardiovascular and haemopoietic systems

1. Cardiac glycosides	274
2. Antiarrhythmics	281
3. Coronary vasodilators	295
4. Analeptics	308
5. Xanthines	316
6. Antihypertensives	321

Table of Contents

7. Peripheral vasodilators	333
8. Normalizers of plasma lipids	344
9. Anticoagulants	352
10. Anti-anaemics	365
11. Plasma substitutes	372
12. Capillary protectors	375
13. Sclerosing agents	381
14. Haemostatics	383
Index	388

Part 1

Drugs acting on the central and peripheral nervous systems and on synaptic junctions

	Page
1. General anaesthetics	2
2. Narcotic analgesics	22
3. Local anaesthetics	37
4. Hypnotics	45
5. Tranquillizers	65
6. Anticonvulsants	119
7. Antidepressants	130
8. Appetite depressants and central stimulants	155
9. Sympathomimetics	164
10. Parasympathomimetics	189
11. Parasympatholytics and spasmolytics	194
12. Muscle relaxants	229
13. Histamines and antihistamines	238
14. Serotonin, antiserotonins, ergot alkaloids, sympatholytics	260

1. GENERAL ANAESTHETICS

General anaesthetics are central nervous system (CNS) depressants which induce loss of consciousness and hence insensibility to pain. Some of these drugs induce relaxation of voluntary muscles. Depression of CNS function is proportional to dose, and as the dose is increased, so is the progressive loss of central function, more recently evolved structures being affected first, e.g., cerebral cortex before thalamus, then hypothalamus, pons, medulla oblongata, and spinal cord.

An ideal general anaesthetic drug should produce analgesia, unconsciousness, amnesia, and relaxation of voluntary muscle. In practice, drugs having only one of these actions are often used in combination. Premedications for anaesthesia are discussed in later chapters, muscle relaxants on page 229, neuroleptics in Vol. 2, and narcotic analgesics on page 22. The drugs to be considered in this chapter are classified as follows:

	Recommendation	Page
<i>Inhalational anaesthetics</i>		
Nitrous oxide	P (NC in labour)	3
Cyclopropane	P (NC in labour)	5
Trichloroethylene	P (NC in labour)	6
Halothane	P	7
Enflurane	P (NC in labour)	10
Methoxyflurane	P (NC in labour)	10
<i>Intravenous anaesthetics</i>		
Thiopentone	NC	13
Methohexitone	NC (P in labour)	15
Propanidid	NC	16
Oxybate sodium	NC	17
Ketamine	NC (P on labour)	18
Alphadolone + Alphaxolone	NC	20

The question of whether volatile anaesthetics are teratogenic to the human embryo is undecided, but such a link has been claimed for occupational exposure to inhalational anaesthetics, particularly amongst female anaesthetists

and operating room nurses. For the average patient there seems to be little problem, but during labour there is a possibility that the use of inhalational anaesthetics may cause neonatal depression. Another problem is that the fluorinated anaesthetics, such as halothane, enflurane, and methoxyflurane, may produce a tocolytic effect, slowing labour. Failure of the uterus to contract post-delivery may cause excessive bleeding. Intravenous anaesthetics may also have important pharmacological effects on the foetus and depress uterine contraction when given in labour.

1.1 Inhalational anaesthetics

Nitrous oxide

(MW 44.01)

ADMINISTRATION	PREGNANCY Trimester			LABOUR	LACTATION
	1	2	3		
Acute					
Chronic	P				

To be used with care in pregnancy, but not contra-indicated in labour.

Nitrous oxide, usually mixed with oxygen, is a popular obstetric analgesic for labour which gives pain relief without loss of consciousness. The usual mode of administration is as a premixed nitrous oxide/oxygen mixture, self-administered by the patient (Entonox). Side effects of nitrous oxide are slight myocardial depression, nausea, vomiting, muscular relaxation, and medullary depression. A true analgesic, nitrous oxide is not a very effective anaesthetic. It is therefore used in combination with barbiturates and muscle relaxants to produce full anaesthesia. Nitrous oxide rapidly crosses the placental barrier [1,2,3,4,5,30,31,37]. Administration of nitrous oxide in labour results in transfer of nitrous oxide to the foetus, and foetal blood concentrations of nitrous oxide are around 50–60% of that in maternal blood [2,4]. During prolonged administration, the concentration in foetal blood reaches a maximum after 15 minutes' administration and may cause foetal narcosis [34]. Earlier in pregnancy possible teratogenic effects of nitrous oxide are not completely excluded. However, this is also true of any other volatile anaesthetic [5,6,7,8,9,10,11,12,38]. In labour, nitrous oxide anaesthesia is relatively free of side effects [1,13,14,15,16,35,36,37]. Transient neonatal respiratory depression has been reported, but this seems to be associated only with prolonged and high dose administration of nitrous oxide [3,17,18,19,20,21,32]. Tocodynamometric studies indicate that nitrous oxide anaesthesia in labour does not affect frequency, intensity, or duration of uterine contractions [22,23,24,33]. The problem of the relationship of teratogenicity to occupational exposure to volatile anaesthetics is discussed in the section on methoxyflurane.

Nitrous oxide is a teratogen in certain laboratory animals such as the rat and the chick embryo [13,15,26,27,28,29]. In the rat, nitrous oxide administered for 2 days in concentrations of 60% by inhalation provoked a significant increase in foetal resorption [26]. When administered for up to 6 days in concentrations of 50% by inhalation it provokes an increase in foetal resorption, abnormal foetuses, and retardation of foetal growth [27]. When nitrous oxide was administered at doses of 1000 – 15 000 ppm for 24 hours from the 8th to the 13th day of pregnancy in the rat, there was a significant increase in foetal resorption [28].

Bibliography

- [1] Bonica J.J.: *Principles and practice of obstetric analgesia & anesthesia* - F.A. Davis Co. Ed. - Philadelphia, 1972.
- [2] Smith C.A.: *Surg. Gyn. Obst.* 70, 787, 1940 (cit. da 1).
- [3] Reginster L.: *Rev. Méd. de Liège* 21, 473, 1966.
- [4] Cohen E.N.: *Surg. Gyn. Obst.* 97, 456, 1953.
- [5] Moya F., Thorndike V.: *Am. J. Obst. Gyn.* 84, 1778, 1962.
- [6] Barber H.R.K., Chamber E.A.: *Surgical disease in pregnancy* - W.B. Saunders Co. Ed. - Philadelphia, 1974.
- [7] Smith B.E.: *Anesth. Analg.* 42, 521, 1963 (cit. da 6).
- [8] Shnider S.M., Webster G.M.: *Am. J. Obst. Gyn.* 92, 891, 1965.
- [9] Braunwald N.S.: *Am. J. Obst. Gyn.* 92, 148, 1965.
- [10] Jacobs W.M., Cooley D., Goen G.P.: *Obst. Gyn.* 24, 167, 1965.
- [11] Meffert W.G., Stansel H.C.: *Am. J. Obst. Gyn.* 102, 1116, 1968.
- [12] Moya F.: *Am. J. Obst. Gyn.* 91, 76, 1965.
- [13] Xavier L.: *Rev. Brasil. Anest.* 20, 525, 1970.
- [14] Goodman L.S., Gilman A.: *The pharmacological basis of therapeutics* - The MacMillan Co. Ed. - New York, 1975.
- [15] Martin E.: *Obst. Gin. Lat. Am.* 34, 121, 1976.
- [16] Romney S.L., Kaneoka T., Gabel P.V.: *Am. J. Obst. Gyn.* 84, 32, 1962.
- [17] Eastman N.J.: *Am. J. Obst. Gyn.* 31, 563, 1936.
- [18] Rooth G.: *Am. J. Obst. Gyn.* 85, 48, 1963.
- [19] Santoli G., Balestra E., Fabiani M.: *Rec. Med.* 3, 1133, 1964.
- [20] Hodges R.J.H.: *Brit. J. Anaesth.* 31, 152, 1959 (cit. da 1).
- [21] Lund C.J.: *Am. J. Obst. Gyn.* 43, 365, 1942.
- [22] Dodek S.M.: *Surg. Gyn. Obst.* 55, 45, 1932 (cit. da 1).
- [23] Van Liere E.J.: *Am. J. Obst. Gyn.* 90, 811, 1964.
- [24] Lindgren L.: *Acta Anaesth. Scand.* 3, 49, 1959.
- [25] Nishimura H., Tanimura T.: *Clinical aspects of the teratogenicity of drugs* - Excerpta Medica Ed. - Amsterdam, 1976.
- [26] Parbrook G.D., Mobbs I., Mackenzie J.: *Brit. J. Anaesth.* 37, 990, 1965 (cit. da 25).
- [27] Fink B.R., Shepard T.H., Blandeau R.J.: *Nature* 214, 146, 1967 (cit. da 25).
- [28] Corbet T.H., Cornell R.G., Endes J.L., Millard R.I.: *Anesthesiology* 39, 299, 1973.
- [29] Smith B.E., Gaub M.L., Moya F.: *Anesth. Analg.* 44, 726, 1965.
- [30] Otteni J.C., Bertrand J.C., Fourine A., Pontonnier G.: *Anesthésie générale chez la femme enceinte* - XXII Congr. Nat. Anesth. Réanim. - Paris, 1972.
- [31] Marx G.F., Joshi C.W., Orkin L.R.: *Anesthesiology* 32, 429, 1970.
- [32] Vasička A.: *Arch. Gynäk.* 202, 333, 1965 (cit. da 30).
- [33] Alfonsi P., Massi G.B.: *Ann. Anesth. Franç.* 5, 23, 1964 (cit. da 30).
- [34] Stenger Y.G., Bechner J.N., Prystowsky H.: *Am. J. Obst. Gyn.* 103, 901, 1969.
- [35] Periti P.: *Farmacologia pediatrica perinatale* - S.E.U. Ed. - Roma, 1973.
- [36] Hay D.M.: *Brit. J. Obst. Gyn.* 85, 299, 1978.
- [37] Rondinelli M., Tambuscio B., Suma V., Donato A., De Laurentiis G.: *Riv. It. Gin.* 58, 29, 1977.
- [38] Howard F.M., Hill J.M.: *Obst. Gyn. Surv.* 34, 643, 1979.